Significant efforts using loss-of-function genetic screens to systematically identify genes essential to the proliferation and survival of cancer cells have been reported^[@R1]--[@R10]^. Genes identified by these approaches may represent specific genetic vulnerabilities of cancer cells, suggesting treatment strategies and directing the development of novel therapeutics. The CRISPR-Cas9 genome editing system has proven to be a powerful tool for multiplexed screening due to its relative ease of application and increased specificity compared to RNA interference technology^[@R11]^.

However, we and others have recently observed that measurements of cell proliferation in genome-scale CRISPR-Cas9 loss-of-function screens are influenced by the genomic copy number (CN) of the region targeted by the sgRNA-Cas9 complex^[@R1],[@R3],[@R4]^. Targeting Cas9 to DNA sequences within regions of high CN gain creates multiple DNA double-strand breaks (DSBs), inducing a gene-independent DNA damage response and a G2 cell-cycle arrest phenotype^[@R3]^. This systematic, sequence-independent effect due to DNA cleavage (*copy-number effect*) confounds the measurement of the consequences of gene deletion on cell viability (*gene-knockout effect*) and is detectable even among low-level CN amplifications and deletions. In particular, this phenomenon hinders interpretation of experiments performed in cancer cell lines that harbor many genomic amplifications since genes in these regions represent a major source of false positives^[@R3],[@R4]^. Existing methods to handle the copy-number effect adopt filtering schemes^[@R9]^, which preclude examination of data from within amplified regions and ignore the effect at low-level alterations. Here, we present CERES, a method to estimate gene dependency from essentiality screens while computationally correcting the copy-number effect, enabling unbiased interpretation of gene dependency at all levels of CN.

As part of our efforts to define a Cancer Dependency Map, a catalog of cell line-specific genetic and chemical vulnerabilities^[@R10],[@R12]^, we performed genome-scale CRISPR-Cas9 loss-of-function screens in 342 cancer cell lines representing 27 cell lineages ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}, <http://depmap.org/ceres>) using the Avana sgRNA library^[@R13]^ ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) and assessed the effects of introducing each sgRNA on cell proliferation (Online Methods). After applying quality control measures, ROC analysis of sgRNAs targeting "gold standard" common core essential and nonessential genes^[@R14]^ demonstrated high screen quality in all cell lines ([Fig. 1a](#F1){ref-type="fig"}). This collection of screens surpasses the scale of existing comparable datasets by roughly tenfold. To confirm the generalizability of our results in independent screens performed with different sgRNA libraries, we reanalyzed two published datasets derived from screens across 33 cancer cell lines of diverse cell lineage (GeCKOv2) ^[@R3]^ and 14 AML cell lines (Wang2017) ^[@R9]^ ([Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}).

Using genomic copy number data from the Cancer Cell Line Encyclopedia (CCLE)^[@R15]^, we assessed the 342 cell lines screened in our Avana dataset for sensitivity to the copy-number effect as in Aguirre *et al.* ^[@R3]^. In consonance with previous observations, the relationship held in every cell line in our panel, where sgRNAs targeting more genomic loci were on average more depleted, frequently to levels at or below the depletion of sgRNAs targeting cell-essential genes ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 1b,c](#SD2){ref-type="supplementary-material"}). In each of the three datasets, some of the observed variability in sensitivity was explained by the p53 mutational status of each line in CCLE ([Supplementary Fig. 1d](#SD2){ref-type="supplementary-material"}).

To quantify the extent to which this sgRNA-level effect translates into false positive gene dependencies, we ranked the genes in each cell line by the average depletion of their targeting sgRNAs (*average guide score*). In an example breast cancer cell line, HCC1419, high-ranking genes were enriched for both genes involved in fundamental cellular processes and genes with amplified CN ([Fig. 1c](#F1){ref-type="fig"}). The depletion ranks of the 100 genes with the largest CN measurements were significantly higher than expected for the majority of cell lines (298/342 with p \< 0.05, one-sample one-tailed K-S test; [Fig. 1d](#F1){ref-type="fig"}, [Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}) and the extent of enrichment was significantly correlated with the average CN of these genes (Spearman ρ = 0.61, p \< 10^−15^), consistent with previous studies ([Supplementary Fig. 2b](#SD2){ref-type="supplementary-material"}).

To decouple the gene-knockout effect from the copy-number effect, we developed CERES, which computationally models the measured sgRNA depletion (*D*) as a sum of these two effects ([Fig. 2](#F2){ref-type="fig"}, Online Methods). Specifically, for each sgRNA *i* and cell line *j,* CERES assumes the following model (**Equation 1**): $$D_{ij} = q_{i}\,\left( {\sum\limits_{k \in G_{i}}\left( h_{k} + g_{kj} \right) + f_{j}\,\left( {\sum\limits_{l \in L_{i}}C_{lj}} \right)} \right) + o_{i} + \varepsilon$$ where ε is a zero-mean, independent Gaussian noise term. The gene-knockout effect is a sum of cell line specific (*g~kj~*) and shared (*h~k~*) effects, which are aggregated across any gene targeted by sgRNA *i* (*G~i~*). The copy-number effect is modeled by a piecewise linear spline, *f~j~*, evaluated at the number of genomic sites targeted, determined by the target loci (*L~i~*) and the CN at each locus (*C~lj~*) (Online Methods). The cumulative depletion effects are then scaled by a *guide activity score* (*q~i~*), restricted to values between 0 and 1, to capture and mitigate the influence of low-quality reagents^[@R13],[@R16],[@R17]^. The offset term *o~i~* accounts for noise in the measurement of sgRNA abundance in the reference pool (Online Methods). CERES infers the gene-knockout effects and all other parameters by fitting the model to the observed data via alternating least squares regression (Online Methods). The inferred gene-knockout effects are then scaled per cell line such that scores of 0 and −1 represent the median effects of nonessential genes and common core essential genes, respectively.

We applied CERES to the Avana dataset of 342 essentiality screens, as well as the GeCKOv2 and Wang2017 datasets, and analyzed the inferred gene-knockout effects ([Supplementary Tables 3--5](#SD1){ref-type="supplementary-material"}). As expected, CERES markedly reduced the relationship between CN and gene dependency found in the uncorrected average guide scores ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 3a](#SD2){ref-type="supplementary-material"}) and removed it nearly entirely among unexpressed genes, determined using CCLE expression data ([Supplementary Fig. 3b](#SD2){ref-type="supplementary-material"}). For each gene, we correlated its CN measurements to its dependency scores before and after correction and found that CERES shifted the mean correlation to near zero ([Supplementary Fig. 3c](#SD2){ref-type="supplementary-material"}). CERES also improved the identification of essential genes in 339 out of 342 screens, as measured by the recall of common core essential genes at a 5% false discovery rate (FDR) of nonessential genes^[@R2]^, by an average of 13.8 percentage points ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 4a](#SD2){ref-type="supplementary-material"}) (Online Methods). This improvement was substantially better than a simple linear model used to correct the relationship between average guide score and CN ([Supplementary Fig. 4b](#SD2){ref-type="supplementary-material"}) (Online Methods). Furthermore, CERES preserved an average of 134 genes per cell line that would have been removed using a simple filtering scheme. On average, six of these filtered genes per cell line scored as essential below a threshold of −0.6 after CERES correction ([Supplementary Fig. 4c](#SD2){ref-type="supplementary-material"}). Reassuringly, CERES preserved expected cancer-specific dependencies, even in amplified regions, such as *KRAS* in an example amplification on chromosome 12p of the DAN-G pancreatic cancer cell line ([Fig. 3c](#F3){ref-type="fig"}, [Supplementary Fig. 5](#SD2){ref-type="supplementary-material"}). Additionally, *KRAS*-mutant cell lines remained substantially enriched over wild-type for *KRAS* gene dependency ([Fig. 3d](#F3){ref-type="fig"}), which generalized to other known oncogenes ([Supplementary Fig. 6](#SD2){ref-type="supplementary-material"}).

CERES estimates a guide activity score for each sgRNA used in the screens ([Supplementary Tables 6--8](#SD1){ref-type="supplementary-material"}). While it is infeasible to experimentally validate the activity of all, or even most, sgRNAs in a genome-scale library, sequence determinants have proven useful in the prediction of on-target activity^[@R13],[@R18],[@R19]^. The Avana sgRNA library was optimized using such predictions. Fittingly, CERES estimated higher guide activity scores on average for the Avana dataset relative to GeCKOv2, with a nearly twenty-fold increase in the ratio of high- to low-activity sgRNAs (161.3 to 1 and 8.3 to 1; [Fig. 4a](#F4){ref-type="fig"}). The guide activity scores for the 4,770 sgRNAs common to both libraries showed substantial agreement (Spearman ρ = 0.53, p \< 10^−15^; [Fig. 4b](#F4){ref-type="fig"}), demonstrating that CERES captured a measure of sgRNA activity that is reproducible across independent collections of screens ([Supplementary Fig. 7a,b](#SD2){ref-type="supplementary-material"}). For both the GeCKOv2 and Avana libraries, we compared CERES guide activity scores to sequence-based predictions of sgRNA activity (Doench-Root scores) ^[@R13]^ and found significant correspondence (Avana: Pearson ρ = 0.21, p \< 10^−15^; GeCKOv2: Pearson ρ = 0.37, p \< 10^−15^; [Fig. 4c](#F4){ref-type="fig"}). Taken together, these results demonstrate that the guide activity scores inferred by CERES are useful for estimating gene-knockout effects and, furthermore, suggests that they could assist in the selection of reagents for follow-up experiments.

To identify cancer-specific genetic vulnerabilities, we used a metric of differential dependency representing the strength of dependency in a cell line relative to all other lines screened (Online Methods). We assessed an upper bound on the number of false positive differential dependencies due to CN amplifications by calculating the percentage of amplified genes at every possible threshold of differential dependency. In the uncorrected data, the percentage of amplified genes increased at stronger dependency thresholds, climbing above 30% at the highest levels of differential dependency, which CERES substantially reduces ([Fig. 5a](#F5){ref-type="fig"}, [Supplementary Fig. 8a](#SD2){ref-type="supplementary-material"}). We next used a similar procedure to examine unexpressed genes, whose deletion or editing is not expected to induce phenotypic effects, and which represent an overt source of false positives if scored as differentially dependent. We found that for genes below a differential dependency of −8, CERES reduced the percentage of unexpressed genes from 6.6% to 0.9%, indicating a substantial improvement in specificity ([Fig. 5b](#F5){ref-type="fig"}, [Supplementary Fig. 8b](#SD2){ref-type="supplementary-material"}).

A dataset of this scale enables the discovery of genetic vulnerabilities specific to a subset of cancer cell lines defined by some cellular context, such as cell lineage. We hypothesized that in this setting, copy-number effects driven by recurrent CN alterations, even with small effect sizes, could introduce false positives. For each gene, we compared average guide scores in 26 breast cancer cell lines to those of all other cell lines (Online methods). Indeed, we found several differential dependencies resident on chromosome 8q, which is recurrently amplified in breast tumors ([Fig. 6a](#F6){ref-type="fig"}). However, when we used CERES-corrected dependency scores, we found that only two of the original chr8q genes, *TRPS1* and *GRHL2*, remained ([Fig. 6b](#F6){ref-type="fig"}). To confirm this finding using a complementary assay, we analyzed this set of genes in a dataset derived from genome-scale RNAi screens across 501 cancer cell lines^[@R20]^. We found that these were the only two genes on chr8q that scored as differentially dependent in the 34 breast lines, while most genes in other regions validated ([Supplementary Fig. 9a,b](#SD2){ref-type="supplementary-material"}). Previous studies have implicated these transcription factors in breast cancer progression^[@R21],[@R22]^, and the high expression levels of these and other transcription factors in breast lines identified suggest that they are likely to be true differential dependencies ([Supplementary Fig. 9c](#SD2){ref-type="supplementary-material"}). We extended this analysis to all cell lineages with recurrently amplified chromosome arms and quantified the enrichment of differential dependencies before and after CERES correction in each context. We observed that CERES reduced the fraction of differential dependencies on the recurrently amplified chromosome arm in 24 out of 25 such cases ([Fig. 6c](#F6){ref-type="fig"}) (Online Methods).

While CERES leverages data across many cell lines to infer guide activity scores, we confirmed that this approach can be applied to datasets of any size - even a screen of a single cell line - given predetermined guide activity scores. These may be pre-computed from a larger set of screens, predicted using available tools, or assumed uniform. In random sub-samplings of cell lines from the Avana dataset, CERES performed nearly as well as when applied to the full set. Furthermore, we tested CERES on single cell lines, using fixed uniform guide activities, and found that the median improvement per cell line was over 97% that of the run on all 342 cell lines ([Supplementary Fig 10](#SD2){ref-type="supplementary-material"}) (Online Methods).

In summary, we introduce a large set of uniformly performed CRISPR-Cas9 essentiality screens of cancer cell lines, propose a methodology to estimate gene dependency while removing false positives due to copy-number effects, and demonstrate the power of these two resources in revealing genetic vulnerabilities of cancer. To facilitate the use of the Avana dataset and CERES, we make the software available as an R package at <https://depmap.org/ceres>, along with all data and analysis scripts used in this study.

Online Methods {#S1}
==============

CRISPR-Cas9 essentiality screening assay {#S2}
----------------------------------------

Cancer cell lines were transduced with a lentiviral vector expressing the Cas9 nuclease under blasticidin selection (pXPR-311Cas9). Each Cas9-expressing cell line was subjected to a Cas9 activity assay^[@R3]^ to characterize the efficacy of CRISPR/Cas9 in these cell lines ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Cell lines with less than 45% measured Cas9 activity were considered ineligible for screening. Stable polyclonal Cas9+ cell lines were then infected in replicate (n = 3) at low multiplicity of infection (MOI \< 1) with a library of 76,106 unique sgRNAs (Avana), which after filtering out sex chromosomes was composed of 70,086 targeting 17,670 genes (\~4 sgRNAs per gene) annotated in the consensus coding sequence (CCDS) database, and 995 non-targeting control sgRNAs ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Cells were selected in puromycin and blasticidin for 7 days and then passaged without selection while maintaining a representation of 500 cells per sgRNA until 21 days after infection. Genomic DNA was purified from endpoint cell pellets, the sgRNA barcodes are PCR amplified with sufficient gDNA to maintain representation, and the PCR products are sequenced using standard Illumina machines and protocols.

Preprocessing and quality control {#S3}
---------------------------------

After sequencing the sgRNA barcodes, raw barcode counts are deconvoluted from sequence data using PoolQ software (<http://portals.broadinstitute.org/gpp/public/dir/download?dirpath=protocols/screening&filename=Pooled_Screening_Deconvolution_using_PoolQ.pdf>) and are summed across sequencing lanes. Samples were removed if they failed to reach 15 million reads. We calculated normalized read counts for each sample according to the procedure in Cowley et al.^[@R7]^. We then calculated pairwise Pearson correlation coefficients between replicate samples from the same cell line to identify and remove poor quality replicates using a threshold of 0.7. All sample read counts were then divided by their representation in the starting plasmid DNA library (pDNA) to compute a fold-change (FC). We computed robust Strictly Standardized Mean Difference (SSMD)^[@R23]^ statistics for the replicates using FCs between non-targeting control sgRNAs and FCs from sgRNAs targeting the spliceosomal, ribosomal, or proteasomal genes in KEGG genesets^[@R24]--[@R26]^. We remove replicates with SSMDs that fail to reach −0.5. We also followed standard fingerprinting procedures to remove mismatched cell lines^[@R7]^. logFC data were then normalized within each cell line replicate by subtracting the median logFC value and dividing by the median average deviation (MAD) before input to CERES.

Copy number data {#S4}
----------------

Copy number data for all cancer cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE)^[@R15]^ data portal (<https://portals.broadinstitute.org/ccle>). CN data were derived from Affymetrix SNP6.0 arrays. Segmentation of normalized log2 ratios was performed using the circular binary segmentation (CBS) algorithm. The dataset is available at (<https://data.broadinstitute.org/ccle_legacy_data/dna_copy_number/CCLE_copynumber_2013-12-03.seg.txt>).

Gene expression and mutation data {#S5}
---------------------------------

Gene expression and mutation data for all cell lines were obtained from CCLE data portal. These datasets are available at <https://data.broadinstitute.org/ccle/CCLE_RNAseq_081117.rpkm.gct> and <https://data.broadinstitute.org/ccle/ccle2maf_081117.txt>.

sgRNA genome mapping {#S6}
--------------------

sgRNA sequences are mapped to the *hg19* reference genome using the bowtie short read aligner, version 1.1.2^[@R27]^. Bowtie was run using the options "-a -v 0" in order to find all perfect matches in the genome. Only sgRNAs with fewer than 100 alignments were included and alignments were filtered to include an NGG protospacer-adjacent motif (PAM). Alignments were then mapped to gene coding sequences using the consensus coding sequence (CCDS) database.

Model fitting {#S7}
-------------

To fit CERES to input data, we solve the following optimization problem: $$\begin{array}{ll}
\underset{\hat{D}}{\text{minimize}} & {\sum\limits_{i = 1}^{M}{\sum\limits_{j = 1}^{N}\left( {D_{ij} - {\hat{D}}_{ij}} \right)^{2}} + \lambda_{g}\sum\limits_{k = 1}^{K}{\sum\limits_{j = 1}^{N}g_{kj}^{2}}} \\
{\text{subjecto}\,\text{to}} & {0 \leq q_{i} \leq 1,i = 1,\ldots,M} \\
\, & {f_{j}(C) \leq f_{j}(C^{\prime}),\forall C \geq C^{\prime} \in {\mathbb{R}}_{\geq 0},j = 1,\ldots,N} \\
\end{array}$$

Where *D̂~ij~* is computed according to Equation (1). The constants *M*, *N*, and *K* in the objective function are, respectively, the total number of sgRNAs, cell lines, and genes in the dataset. The right-hand term in the objective function acts as a regularizer on the cell-line specific deviation from the shared gene-knockout effect, where the hyperparameter λ~g~ modulates the strength of the regularization. The first constraint on the model parameters ensures that the guide activity scores are between 0 and 1. The second constraint guarantees that the copy-number effect functions are monotonically decreasing in their arguments. As the objective function is not jointly convex in the model parameters, we fit CERES using alternating least squares, first solving for the gene essentiality scores and copy-number effect parameters with the guide activity scores and offsets held constant, then solving for the guide activity scores and offsets as follows:

###### 

CERES alternating minimization.

  -------------------- ----------------------------------------------------------------------------------------------------
  **given** *ε* \> 0   
  **initialize**       
  1\.                  *gene-knockout and copy-number effect coefficients* \[*g*, *f*\] := \[0,0\]
  2\.                  *guide activity scores and offsets* \[*q*, *o*\] := \[1,0\]
  **repeat**           
  1\.                  *Solve for gene-knockout and copy-number effects.* Compute optimal parameters \[*g*^\*^, *f*^\*^\]
  2\.                  *Update.* \[*g*^\*^, *f*^\*^\] := \[*g*^\*^, *f*^\*^\]
  *3.*                 *Solve for guide activity scores and offsets.* Compute optimal parameters \[*q*^\*^, *o*^\*^\]
  *4.*                 *Update.* \[*q*^\*^, *o*^\*^\] := \[*q*^\*^, *o*^\*^\]
  *5.*                 *Evaluate mean squared error (mse). mse~t~* := \|\|*D* − *D̂*\|\|^2^/*MN*
  6\.                  *Evaluate decrease in error.* Δ*mse* := *mse~t~* − *mse~t~*~−1~
  *7.*                 *Stopping criterion.* **quit** if Δ*mse* \< *ε*
  -------------------- ----------------------------------------------------------------------------------------------------

Due to the presence of constraints, we use numerical optimization techniques to solve for the optimal parameters \[*g*^\*^, *f*^\*^\] and \[*q*^\*^, *o*^\*^\] in steps 1 and 3^[@R28]^. Note that we use the bracket notation \[*g*, *f*\] to indicate that the enclosed parameters are inferred simultaneously as variables in a system of constrained linear equations.

Spline functions {#S8}
----------------

The piecewise linear spline functions *f~j~* in the CERES model equations allow for flexible modeling of the characteristic saturation of the copy-number effect at high numbers of cuts. They are implemented with B-spline regression methods and are each parameterized by 25 slope coefficients plus a single intercept parameter. These are inferred directly in the regression that determines the gene-knockout effects. Each spline has an initial knot point at CN = 0. The additional knot points are determined by running average linkage clustering on the CN data for each cell line.

Hyperparameter optimization and test set evaluation {#S9}
---------------------------------------------------

To improve the generalizability of our model and minimize overfitting of the training data, we regularized the cell line specific gene effects. To find the best value of λ~g~, we evaluated the mean squared error (MSE) obtained on a randomly selected held-out validation set (one-tenth of all observations) for each of 25 values of λ~g~ sampled log-uniformly from the interval \[0.01, 1\]. After the 25 models were evaluated, the value of λ~g~ yielding the lowest MSE was used to fit the final model on the full set of observations ([Supplementary Fig. 11](#SD2){ref-type="supplementary-material"}). The optimized value of λ~g~ was 0.562, 0.681, and 0.681 for the Avana, GeCKOv2, and Wang2017 datasets, respectively.

Model complexity {#S10}
----------------

Given a collection of CRISPR screening data, let *N* be the number of sgRNAs, *M* be the number of cell lines, and *K* be the number of targeted genes in the dataset. CERES fits *KM* cell line specific gene effect parameters and an additional *K* parameters for the shared gene effects. The model also fits *M(S + 1)* copy-number effect parameters, where *S* is the number of CN segments in each piecewise linear spline, and *2N* parameters for the guide activity scores and offsets. Ignoring the degrees of freedom lost by regularization and constraints, CERES takes in *MN* data points and fits *MN(1/N + S/N + 2/M + K/N + K/MN)* parameters.

Software and implementation {#S11}
---------------------------

Matrix operations for the optimization procedure were implemented using the open source C++ linear algebra library Eigen, version 3.3, available at <http://eigen.tuxfamily.org>. These operations were then wrapped into the R statistical software using the 'RcppEigen' package, downloaded from <http://cran.r-project.org>. The optimization routine and final fit for each dataset were run using Google Cloud Platform services.

Precision-recall analysis {#S12}
-------------------------

Precision-recall curves were generated using the sets of common core essential and nonessential genes defined in Hart *et al.* ^[@R14]^. The best threshold for which greater than 95% of hits are essential genes is calculated for an FDR of 5%. The percentage of all essential genes that score as hits at this threshold is calculated as the recall at 5% FDR.

Comparison with linear regression {#S13}
---------------------------------

For each cell line, average guide scores were regressed against gene-level copy number data using a linear model. The fit residuals are taken as the LM-corrected gene dependency scores. Precision-recall analysis was performed as above.

Subsampling analysis {#S14}
--------------------

We simulated CERES performance generalization to other dataset sizes by downsampling from the Avana dataset. Specifically, for each number *p* in the set {1, 2, 4, 8, 16, 32, 64} we ran $\frac{342}{p}$ trials (up to rounding), such that each cell line appeared once in each run of size *p*. For each *p* and each cell line, we evaluated the harmonic mean of precision and recall (referred to as the F1-measure) at the point of equiprobability between the essential and nonessential gene classes. We then compared this number to the F1-measure obtained by running CERES on the full Avana dataset. For *p* \< 5 we fixed all guide activity scores to a value of 1.

Differential dependency {#S15}
-----------------------

Differential dependency is calculated as the difference between a single cell line's dependency score for a given gene and the mean score for that gene across all lines screened, and then z-score normalized to that cell line's entire set of differential dependencies to reduce the influence of noisy cell lines. For calculating the fraction of differential dependencies that are amplified or unexpressed, only genes with a negative dependency score in at least one cell line are considered.

Recurrent chromosome arm amplifications {#S16}
---------------------------------------

We called recurrent chromosome arm amplifications for a lineage across the entire CCLE CN dataset. A chromosome arm was called as amplified if the weighted median of copy number segments on that arm was greater than 2.8. Recurrently amplified chromosome arms for a lineage were then defined using a one-tailed Fisher's exact test to test for enrichment of amplified arms in that lineage, at an FDR-corrected p-value of 0.05.

Lineage-specific differential dependencies {#S17}
------------------------------------------

For every lineage in our dataset with at least five cell lines, we calculate the difference in means in gene dependency between cell lines of that lineage and the rest of the dataset, and assess significance with a two-tailed student's t-test (df=340), for each gene screened. Differential dependencies are called with a negative effect size at a significance of FDR-corrected p-value \< 0.05. For each chromosome arm that was recurrently amplified for that lineage, we calculate the fraction of significant differential dependencies on that chromosome arm before and after CERES correction.

Supplementary Material {#S18}
======================

###### 

**Supplementary Table 1**. Sample information for the 342 cancer cell lines used in this study.

**Supplementary Table 2.** sgRNA barcode sequences included in the Avana library with genome and coding sequence mappings.

**Supplementary Table 3.** CERES-estimated gene-knockout effects for 342 cancer cell lines screened with the Avana sgRNA library.

**Supplementary Table 4.** CERES-estimated gene-knockout effects for 33 cancer cell lines screened with the GeCKOv2 sgRNA library published in Aguirre et al. (2016).

**Supplementary Table 5.** CERES-estimated gene-knockout effects for 14 AML cell lines screened with the Wang2017 sgRNA library published in Wang et al. (2017).

**Supplementary Table 6.** CERES-estimated guide activity scores for sgRNAs in the Avana dataset.

**Supplementary Table 7.** CERES-estimated guide activity scores for sgRNAs in the GeCKOv2 dataset.

**Supplementary Table 8.** CERES-estimated guide activity scores for sgRNAs in the Wang2017 dataset.
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![Genomic copy number confounds the interpretation of CRISPR-Cas9 loss-of-function proliferation screens of cancer cell lines\
(**a**) Screen quality for each cell line in the panel (n=342), as measured by area under the receiver operating characteristic curve (AUC) in discriminating between predefined sets of common core essential and nonessential genes. (**b**) The depletion of sgRNAs is regressed against the number of perfect-match genomic cut sites using a simple saturating linear fit, which is plotted for each cell line, colored by lineage, and scaled such that the median of sgRNAs targeting cell-essential genes is at −1, marked by a dashed line. (**c**) Genes are ranked by the mean depletion of targeting sgRNAs (average guide score) and plotted for an example cell line. Values of 0 and −1 represent the median scores of nonessential and cell-essential genes, respectively, indicated by dashed lines. Below, depletion ranks of genes involved in fundamental cell processes and genes at various ranges of CN amplification are shown. (**d**) The median and interquartile range (IQR) of depletion ranks for the 100 most amplified genes per cell line are plotted. Color indicates mean amplification level of these genes. The gray-shaded area indicates the IQR of all genes screened.](nihms910985f1){#F1}

![Schematic of the CERES computational model\
As input, CERES takes sgRNA depletion and CN data for all cell lines screened. During the inference procedure, CERES models the depletion values as a sum of gene-knockout and copy-number effects, multiplied by a guide activity score parameter. CERES then outputs the values of the parameters that produce the highest likelihood of the observed data under the model.](nihms910985f2){#F2}

![CERES corrects the copy-number effect and improves the specificity of fCRISPR-Cas9 essentiality screens while preserving true gene dependencies\
(**a**) Boxplots of gene dependency scores are shown across CN for uncorrected average guide scores and CERES gene dependency scores. Data are scaled as in [Fig. 1c](#F1){ref-type="fig"}. (**b**) The recall of cell-essential genes at a 5% FDR of nonessential genes is plotted for each cell line before (red) and after (blue) CERES correction. Precision-recall curves are inset for example cell lines with poor recall (bottom left) and good recall (top right) before CERES correction. (**c**) An example amplified region on chromosome 12p is shown for the DAN-G pancreatic cell line. The top track represents CN with amplifications shown in red. The middle track and bottom tracks show the average guide score and CERES score, respectively, for each gene in this region. The purple line is representing the median value in each CN segment. *KRAS* is highlighted in orange. (**d**) *KRAS* gene dependency and CN are shown for all cell lines after CERES correction, with mutant *KRAS* lines in orange.](nihms910985f3){#F3}

![CERES estimates guide activity scores for each sgRNA\
(**a**) sgRNAs are binned into groups with high (0.9--1), moderate (0.2--0.9), and low (0--0.2) guide activity scores. The compositions of guide activity scores are shown for the set of screens performed with the GeCKOv2 and the Avana sgRNA libraries. (**b**) For the set of 4,770 sgRNAs shared between the GeCKOv2 and Avana libraries, sgRNAs are ranked by guide activity scores in each dataset and are plotted against each other, with darker blue representing a greater density of sgRNAs. (**c**) sgRNAs are binned by predicted on-target activity using the Doench-Root score, and the composition of CERES-estimated guide activity scores is shown for each dataset.](nihms910985f4){#F4}

![CERES reduces false positive differential dependencies\
(**a**) The percentage of genes on amplified regions (CN \> 4) below a given differential dependency threshold is plotted for the uncorrected average guide score in red and the CERES gene dependency score in blue. (**b**) The percentage of unexpressed genes (log~2~RPKM \< −1) below a given differential dependency score is plotted as in (a).](nihms910985f5){#F5}

![CERES reduces false positives among lineage-specific differential dependencies due to recurrently amplified chromosome arms\
(**a**) The distributions of differential dependencies in breast lines are plotted red for genes on chromosome 8q (commonly gained in breast tumors) and black for all other genes. Below, the differential dependency of each gene is plotted against the FDR-corrected p-value, calculated from a student's t-test, with colors as above. The dashed line represents an FDR of 5%. (**b**) Data are shown for CERES-inferred gene effects as in (a). (**c**) The percentages of lineage-specific differential dependencies (FDR \< 0.05) that are on recurrently amplified chromosome arms are shown, before and after CERES correction.](nihms910985f6){#F6}

  Name                                           Source                      Lineage                  Histology                                                    Gender   Age    Primary/Metastasis   Achilles culture medium
  ---------------------------------------------- --------------------------- ------------------------ ------------------------------------------------------------ -------- ------ -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  143B_BONE                                      CCLE                        Osteosarcoma             osteosarcoma                                                 female   13     primary              EMEM; 10% FBS; 0.015 mg/ml 5-bromo-2′-seoxyuridine
  42MGBA_CENTRAL_NERVOUS_SYSTEM                  CCLE                        Glioma                   glioma                                                       NA       NA     NA                   RPMI 1640 + EMEM (1:1): 80.0%
  5637_URINARY_TRACT                             CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  59M_OVARY                                      CCLE                        Ovary                    carcinoma                                                    NA       NA     NA                   "DMEM; 10% FBS + 2 mM Glutamine, sodium pyruvate, ITS"
  639V_URINARY_TRACT                             CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS
  647V_URINARY_TRACT                             CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   "DMEM; 15% FBS, 2mMGlutamax-1"
  769P_KIDNEY                                    CCLE                        Kidney                   carcinoma                                                    female   63     primary              RPMI; 10% FBS
  786O_KIDNEY                                    CCLE                        Kidney                   carcinoma                                                    male     58     primary              RPMI; 10% FBS
  8305C_THYROID                                  CCLE                        Thyroid                  carcinoma                                                    NA       NA     NA                   RPMI-1640: 85.0%
  8MGBA_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       NA       NA     NA                   EMEM: 80.0%
  A2058_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           male     43     metastasis           DMEM; 10% FBS
  A2780_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   NA     primary              RPMI; 10% FBS
  A549_LUNG                                      CCLE                        Lung (NSCLC)             carcinoma                                                    male     58     primary              DMEM; 10% FBS
  ABC1_LUNG                                      CCLE                        Lung (NSCLC)             carcinoma                                                    male     47     primary              EMEM; 10% FBS
  AGS_STOMACH                                    CCLE                        Stomach                  carcinoma                                                    female   54     primary              F12K; 10% FBS
  ASPC1_PANCREAS                                 CCLE                        Pancreas                 carcinoma                                                    female   62     metastasis           RPMI; 10% FBS
  AU565_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   43     metastasis           DMEM; 10% FBS
  BC3C_URINARY_TRACT                             CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   M10
  BFTC905_URINARY_TRACT                          CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   DMEM: 90.0%
  BFTC909_KIDNEY                                 CCLE                        Kidney                   carcinoma                                                    male     64     primary              DMEM; 10% FBS
  BHY_UPPER_AERODIGESTIVE_TRACT                  CCLE                        Upper Aerodigestive      carcinoma                                                    male     NA     NA                   DMEM; 10% FBS
  BICR22_UPPER_AERODIGESTIVE_TRACT               CCLE                        Upper Aerodigestive      carcinoma                                                    male     NA     primary              DMEM; 10% FBS; 2mM Glutamine; 0.4ug/ml hydrocortisone
  BICR6_UPPER_AERODIGESTIVE_TRACT                CCLE                        Upper Aerodigestive      carcinoma                                                    male     NA     NA                   DMEM; 10% FBS
  BT549_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   72     primary              RPMI; 10% FBS; 10 ug/ml insulin
  C2BBE1_LARGE_INTESTINE                         CCLE                        Colorectal               carcinoma                                                    male     72     primary              DMEM; 10% FBS; 0.01mg/ml transferrin; 2 mM glutamine
  C32_SKIN                                       CCLE                        Melanoma                 malignant_melanoma                                           male     53     primary              EMEM; 10% FBS; 0.1mM NEAA
  CAKI1_KIDNEY                                   CCLE                        Kidney                   carcinoma                                                    male     49     metastasis           McCoy's 5A; 10% FBS
  CAKI2_KIDNEY                                   CCLE                        Kidney                   carcinoma                                                    male     69     primary              McCoy's 5A; 10% FBS
  CAL27_UPPER_AERODIGESTIVE_TRACT                CCLE                        Upper Aerodigestive      carcinoma                                                    male     56     primary              DMEM; 10% FBS
  CAL29_URINARY_TRACT                            CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS
  CAL51_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   45     metastasis           DMEM; 20% FBS
  CAL78_BONE                                     CCLE                        Chondrosarcoma           chondrosarcoma                                               NA       NA     NA                   "RPMI-1640, 20% FBS"
  CALU6_LUNG                                     CCLE                        Lung (NSCLC)             carcinoma                                                    female   61     primary              EMEM; 10% FBS
  CAMA1_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   51     metastasis           EMEM; 10% FBS
  CAOV3_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   54     primary              DMEM; 10% FBS
  CAS1_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       male     63     primary              DMEM; 10% FBS
  CCFSTTG1_CENTRAL_NERVOUS_SYSTEM                CCLE                        Glioma                   glioma                                                       NA       NA     NA                   RPMI; 10% FBS
  CCK81_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   "EMEM, 10% FBS"
  CFPAC1_PANCREAS                                CCLE                        Pancreas                 carcinoma                                                    male     26     primary              DMEM; 10% FBS
  CHAGOK1_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     45     primary              RPMI; 10% FBS; 2mM glutamine
  CHP212_AUTONOMIC_GANGLIA                       CCLE                        Neuroblastoma            neuroblastoma                                                NA       NA     NA                   EMEM:F12 (1:1); 10% FBS
  CJM_SKIN                                       CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     metastasis           Hams F-12; 10% FBS
  CL40_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   "DMEM/F-12 (1:1), 20% FBS"
  COLO678_LARGE_INTESTINE                        CCLE                        Colorectal               carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  COLO679_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           female   47     metastasis           RPMI; 10% FBS
  COLO792_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           male     62     metastasis           RPMI; 10% FBS
  COLO800_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           male     14     primary              RPMI-1640; 10%FBS
  CORL279_LUNG                                   CCLE                        Lung (SCL)               carcinoma                                                    male     63     metastasis           RPMI; 10% FBS; 2mM glutamine
  CORL47_LUNG                                    CCLE                        Lung (SCL)               carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  COV318_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   NA     primary              EMEM; 10% FBS
  COV362_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   NA     primary              DMEM; 10% FBS; 2mM L-glutamine
  COV434_OVARY                                   CCLE                        Ovary                    sex_cord-stromal_tumour                                      female   NA     primary              DMEM; 10% FBS; 2mM L-glutamine
  COV504_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   NA     primary              DMEM; 10% FBS; 2mM L-glutamine
  COV644_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   NA     primary              DMEM; 10% FBS; 2mM L-glutamine
  D283MED_CENTRAL_NERVOUS_SYSTEM                 CCLE                        Medulloblastoma          primitive_neuroectodermal_tumour-medulloblastoma             male     NA     NA                   "DMEM; 10% FBS; 2mM L-glutamine, 2mM sodium pyruvate"
  D341MED_CENTRAL_NERVOUS_SYSTEM                 CCLE                        Medulloblastoma          primitive_neuroectodermal_tumour-medulloblastoma             male     NA     NA                   DMEM:F12 (1:1); 15% FBS
  DANG_PANCREAS                                  CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  DAOY_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Medulloblastoma          primitive_neuroectodermal_tumour-medulloblastoma             NA       NA     NA                   EMEM: 90.0% 10%FBS
  DETROIT562_UPPER_AERODIGESTIVE_TRACT           CCLE                        Upper Aerodigestive      carcinoma                                                    female   NA     NA                   EMEM; 10% FBS
  DKMG_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       female   67     primary              RPMI; 10% FBS; 2mM glutamine
  DLD1_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    male     NA     primary              RPMI; 10% FBS
  DU4475_BREAST                                  CCLE                        Breast                   carcinoma                                                    female   70     metastasis           RPMI; 10% FBS
  EFM19_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   50     metastasis           RPMI; 10% FBS
  EFO21_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   56     metastasis           RPMI; 20% FBS; 0.1mM NEAA; 1mM Sodium Pyruvate
  EFO27_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   36     metastasis           RPMI; 20% FBS; 0.1mM NEAA; 1mM Sodium Pyruvate
  EKVX_LUNG                                      CCLE                        Lung (NSCLC)             carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  EPLC272H_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     57     primary              RPMI; 20% FBS
  ES2_OVARY                                      CCLE                        Ovary                    carcinoma                                                    female   47     primary              RPMI; 10% FBS
  ESS1_ENDOMETRIUM                               CCLE                        Endometrium              carcinoma                                                    female   76     primary              RPMI; 20% FBS
  F5_CENTRAL_NERVOUS_SYSTEM                      "Dunn Lab, Harvard"         Meningioma               meningioma                                                   male     NA     NA                   RPMI; 10% FBS
  FADU_UPPER_AERODIGESTIVE_TRACT                 CCLE                        Upper Aerodigestive      carcinoma                                                    male     NA     NA                   EMEM; 10% FBS
  FU97_STOMACH                                   CCLE                        Stomach                  carcinoma                                                    female   NA     NA                   DMEM;10% FBS; Human Insulin: 0.01 mg/mL
  G292CLONEA141B1_BONE                           CCLE                        Osteosarcoma             osteosarcoma                                                 NA       NA     NA                   McCoy's 5A; 10% FBS
  G401_SOFT_TISSUE                               CCLE                        Soft Tissue              rhabdoid_tumour                                              male     0.25   primary              McCoy's 5A; 10% FBS
  GAMG_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       NA       NA     NA                   "DMEM, 10%FBS, 2mM Glutamax-1"
  GB1_CENTRAL_NERVOUS_SYSTEM                     CCLE                        Glioma                   glioma                                                       male     35     primary              EMEM; 10% FBS
  GCIY_STOMACH                                   CCLE                        Stomach                  carcinoma                                                    female   NA     primary              MEM; 15% FBS
  GI1_CENTRAL_NERVOUS_SYSTEM                     CCLE                        Glioma                   glioma                                                       NA       NA     NA                   DMEM: 90.0%
  GSS_STOMACH                                    CCLE                        Stomach                  carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  H4_CENTRAL_NERVOUS_SYSTEM                      CCLE                        Glioma                   glioma                                                       NA       NA     NA                   DMEM: 90.0%
  HARA_LUNG                                      CCLE                        Lung (NSCLC)             carcinoma                                                    male     57     primary              RPMI; 10% FBS
  HCC1143_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   52     primary              RPMI; 10% FBS
  HCC1359_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    female   55     primary              RPMI; 10% FBS
  HCC1395_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   43     primary              RPMI; 10% FBS
  HCC1419_BREAST                                 CCLE                        Breast                   carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  HCC1428_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   49     metastasis           RPMI; 10% FBS
  HCC15_LUNG                                     CCLE                        Lung (NSCLC)             carcinoma                                                    male     47     primary              RPMI; 10% FBS
  HCC1806_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   60     primary              RPMI; 10% FBS
  HCC1937_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   24     primary              RPMI; 10% FBS
  HCC1954_BREAST                                 CCLE                        Breast                   carcinoma                                                    female   61     primary              RPMI; 10% FBS
  HCC202_BREAST                                  CCLE                        Breast                   carcinoma                                                    female   82     primary              RPMI; 10% FBS
  HCC56_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   EMEM; 10% FBS
  HCC827_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    female   39     primary              RPMI; 10% FBS
  HCC95_LUNG                                     CCLE                        Lung (NSCLC)             carcinoma                                                    male     65     primary              RPMI; 10% FBS
  HEC1A_ENDOMETRIUM                              CCLE                        Endometrium              carcinoma                                                    female   71     primary              McCoy's 5A; 10% FBS
  HEC1B_ENDOMETRIUM                              CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   EMEM; 10%FBS
  HEC251_ENDOMETRIUM                             CCLE                        Endometrium              carcinoma                                                    female   NA     primary              EMEM; 0.15% FBS
  HEC50B_ENDOMETRIUM                             CCLE                        Endometrium              carcinoma                                                    female   NA     primary              EMEM; 15% FBS
  HEC59_ENDOMETRIUM                              CCLE                        Endometrium              carcinoma                                                    female   NA     primary              EMEM; 0.15% FBS
  HEC6_ENDOMETRIUM                               CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   EMEM; 15% FBS
  HEYA8_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   NA     primary              RPMI; 10% FBS
  HGC27_STOMACH                                  CCLE                        Stomach                  carcinoma                                                    NA       NA     NA                   Minimum Essential Media (MEM); 10% FBS; NEAA( Non-essential Amino Acids): 5.0 ml; L-glutamine: 2.0 mM
  HLF_LIVER                                      CCLE                        Liver                    carcinoma                                                    male     69     primary              EMEM; 10% FBS
  HMC18_BREAST                                   CCLE                        Breast                   carcinoma                                                    NA       NA     NA                   RPMI-1640: 10%FBS
  HOP62_LUNG                                     CCLE                        Lung (NSCLC)             carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  HS294T_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           male     56     metastasis           DMEM; 10% FBS
  HS578T_BREAST                                  CCLE                        Breast                   carcinoma                                                    female   74     primary              DMEM; 10% FBS
  HS683_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       male     76     primary              DMEM; 10% FBS
  HS695T_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           male     NA     NA                   EMEM: 10% FBS
  HS729_SOFT_TISSUE                              CCLE                        Soft Tissue              rhabdomyosarcoma                                             NA       NA     NA                   DMEM; 5% FBS
  HS766T_PANCREAS                                CCLE                        Pancreas                 carcinoma                                                    male     46     primary              DMEM; 10% FBS
  HS944T_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           male     51     metastasis           DMEM; 10% FBS
  HSC3_UPPER_AERODIGESTIVE_TRACT                 CCLE                        Upper Aerodigestive      carcinoma                                                    male     64     primary              EMEM; 10% FBS
  HT1080_SOFT_TISSUE                             CCLE                        Soft Tissue              fibrosarcoma                                                 male     35     metastasis           EMEM; 10% FBS
  HT115_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   DMEM; 15% FBS; 2mM Glutamax-1
  HT1197_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    male     44     primary              EMEM; 10% FBS
  HT1376_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   EMEM; 10% FBS
  HT144_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           male     NA     NA                   McCoy's 5A; 10% FBS
  HT55_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    NA       NA     primary              EMEM; 20% FBS; 2mM L-glutamine; 0.1mM NEAA
  HUH1_LIVER                                     CCLE                        Liver                    carcinoma                                                    male     35     primary              DMEM; 10% FBS
  HUH6_LIVER                                     CCLE                        Liver                    other                                                        NA       NA     NA                   DMEM; 10% FBS
  HUH7_LIVER                                     CCLE                        Liver                    carcinoma                                                    male     57     primary              DMEM; 10% FBS
  HUPT3_PANCREAS                                 CCLE                        Pancreas                 carcinoma                                                    male     66     primary              MEM; 10% FBS
  IGR1_SKIN                                      CCLE                        Melanoma                 malignant_melanoma                                           male     42     metastasis           DMEM; 10% FBS
  IGR39_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           male     26     primary              DMEM; 15% FBS
  IMR32_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   EMEM; 10% FBS
  IPC298_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           female   64     primary              RPMI; 10% FBS
  JHH1_LIVER                                     CCLE                        Liver                    carcinoma                                                    male     50     primary              William's E Medium; 10% FBS
  JHH4_LIVER                                     CCLE                        Liver                    carcinoma                                                    NA       NA     NA                   EMEM; 10% FBS
  JHH5_LIVER                                     CCLE                        Liver                    carcinoma                                                    male     50     primary              William's E Medium: 90.0%
  JHH7_LIVER                                     CCLE                        Liver                    carcinoma                                                    NA       NA     NA                   William's E medium with 10% FCS
  JHOC5_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   NA     primary              DMEM:F12 (1:1); 10% FBS; 0.1mM NEAA
  JHOM1_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   NA     primary              DMEM:F12 (1:1); 10% FBS; 0.1mM NEAA
  JHOS2_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   45     primary              DMEM/F12 (1:1);10 % FBS;
  JHOS4_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   44     primary              DMEM:F12 (1:1); 10% FBS
  JIMT1_BREAST                                   CCLE                        Breast                   carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  JMSU1_URINARY_TRACT                            CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS; 2mM Glutamax-1
  K029AX_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     primary              RPMI; 10% FBS
  KALS1_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       female   NA     primary              RPMI; 5% FBS
  KARPAS299_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE   "Weinstock Lab, DFCI"       T-cell Lymphoma (ALCL)   lymphoid_neoplasm                                            male     NA     NA                   "RPMI, 20% FBS, 2 mM L-glutamine"
  KELLY_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                NA       NA     NA                   RPMI; 10% FBS
  KIJK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE        "Weinstock Lab, DFCI"       T-cell Lymphoma (ALCL)   lymphoid_neoplasm                                            male     NA     NA                   RPMI; 20% FBS
  KLE_ENDOMETRIUM                                CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   "DMEM/F-12 (1:1), 10%FBS"
  KM12_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  KMBC2_URINARY_TRACT                            CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS
  KMRC1_KIDNEY                                   CCLE                        Kidney                   carcinoma                                                    male     NA     primary              DMEM; 10% FBS
  KMRC20_KIDNEY                                  CCLE                        Kidney                   carcinoma                                                    NA       NA     primary              DMEM; 10% FBS
  KNS42_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       NA       NA     NA                   EMEM; 5% FBS
  KNS60_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       male     55     primary              DMEM; 0.05% FBS
  KNS62_LUNG                                     CCLE                        Lung (NSCLC)             carcinoma                                                    male     49     primary              EMEM; 20% FBS
  KNS81_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       male     65     primary              DMEM; 5% FBS
  KP2_PANCREAS                                   CCLE                        Pancreas                 carcinoma                                                    female   65     primary              RPMI; 10% FBS
  KP3_PANCREAS                                   CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  KP4_PANCREAS                                   CCLE                        Pancreas                 carcinoma                                                    male     50     metastasis           DMEM:F12 (1:1); 10% FBS
  KPL1_BREAST                                    CCLE                        Breast                   carcinoma                                                    female   50     metastasis           DMEM; 10% FBS
  KPNYN_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                NA       NA     NA                   RPMI; 10% FBS
  KS1_CENTRAL_NERVOUS_SYSTEM                     CCLE                        Glioma                   glioma                                                       NA       NA     NA                   MEM; 10% FBS; 2mMGlutamax-1
  KU1919_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   RPMI; 10%heat inactive FBS
  KURAMOCHI_OVARY                                CCLE                        Ovary                    carcinoma                                                    female   NA     primary              RPMI; 10% FBS
  KYSE180_OESOPHAGUS                             CCLE                        Esophagus                carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  KYSE270_OESOPHAGUS                             CCLE                        Esophagus                carcinoma                                                    NA       NA     NA                   RPMI 1640:F12 (1:1): 90.0%
  KYSE30_OESOPHAGUS                              CCLE                        Esophagus                carcinoma                                                    male     64     primary              RPMI:F12 (1:1); 20% FBS
  KYSE410_OESOPHAGUS                             CCLE                        Esophagus                carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  KYSE450_OESOPHAGUS                             CCLE                        Esophagus                carcinoma                                                    male     59     primary              RPMI:HamsF-12(1:1) (RPMI-1640 (Hyclone Cat.\# SH30027.02):Hams F-12 (Hyclone Cat.\# SH30026.01)); 10% FBS
  KYSE70_OESOPHAGUS                              CCLE                        Esophagus                carcinoma                                                    male     77     primary              RPMI; 10% FBS
  LCLC103H_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     61     metastasis           RPMI; 10% FBS
  LI7_LIVER                                      CCLE                        Liver                    carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  LK2_LUNG                                       CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     primary              DMEM; 10% FBS
  LN18_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       male     65     primary              DMEM; 5% FBS
  LN235_CENTRAL_NERVOUS_SYSTEM                   "Lynda Chin, MD Anderson"   Glioma                   glioma                                                       male     NA     NA                   DMEM; 10% FBS
  LN382_CENTRAL_NERVOUS_SYSTEM                   "Lynda Chin, MD Anderson"   Glioma                   glioma                                                       male     NA     NA                   DMEM; 10% FBS
  LN443_CENTRAL_NERVOUS_SYSTEM                   "Mikael Rinne, DFCI"        Glioma                   glioma                                                       male     NA     NA                   DMEM; 10% FBS
  LNZ308_CENTRAL_NERVOUS_SYSTEM                  "Lynda Chin, MD Anderson"   Glioma                   glioma                                                       female   NA     NA                   DMEM; 10% FBS
  LOVO_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    male     56     metastasis           F12K; 10% FBS
  LS1034_LARGE_INTESTINE                         CCLE                        Colorectal               carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  LS180_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    female   NA     NA                   EMEM; 10% FBS
  LS513_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    male     63     primary              RPMI; 10% FBS
  LUDLU1_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    male     72     primary              RPMI; 10% FBS
  LXF289_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    male     63     primary              Hams F-12; 10% FBS
  M059K_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       male     33     primary              DMEM/F12 (1:1); 10 % FBS
  MALME3M_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           male     43     metastasis           RPMI; 10% FBS
  MCAS_OVARY                                     CCLE                        Ovary                    carcinoma                                                    NA       NA     NA                   EMEM:15%FBS
  MDAMB157_BREAST                                CCLE                        Breast                   carcinoma                                                    female   44     metastasis           RPMI; 10% FBS
  MDAMB231_BREAST                                CCLE                        Breast                   carcinoma                                                    female   51     metastasis           RPMI; 10% FBS
  MDAMB415_BREAST                                CCLE                        Breast                   carcinoma                                                    female   38     metastasis           L-15; 15% FBS; 2mM glutamine; 10mcg/mL Insulin; 10mcg/mL Glutathione
  MDAMB435S_SKIN                                 CCLE                        Melanoma                 malignant_melanoma                                           female   NA     NA                   RPMI; 10% FBS
  MDAMB436_BREAST                                CCLE                        Breast                   carcinoma                                                    female   43     metastasis           RPMI; 10% FBS; 16ug/ml glutathione
  MDAMB453_BREAST                                CCLE                        Breast                   carcinoma                                                    female   48     metastasis           RPMI; 10% FBS
  MDAMB468_BREAST                                CCLE                        Breast                   carcinoma                                                    female   51     metastasis           DMEM; 10% FBS
  MDST8_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS; 2mM Glutamine
  MELHO_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           female   NA     primary              RPMI; 10% FBS
  MELJUSO_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           female   NA     NA                   RPMI; 10% FBS
  MFE319_ENDOMETRIUM                             CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   40% RPMI 1640 + 40% MEM (with Earle's salts) + 20% h.i. FBS
  MHHNB11_AUTONOMIC_GANGLIA                      CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   RPMI; 10% FBS
  MIAPACA2_PANCREAS                              CCLE                        Pancreas                 carcinoma                                                    male     65     primary              DMEM; 10% FBS
  MKN45_STOMACH                                  CCLE                        Stomach                  carcinoma                                                    female   62     metastasis           RPMI; 10% FBS
  MOLM13_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE      CCLE                        AML                      haematopoietic_neoplasm                                      male     20     primary              RPMI; 20% FBS
  MORCPR_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  MV411_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE       CCLE                        AML                      haematopoietic_neoplasm                                      male     10     primary              IMDM; 10% FBS
  NB1_AUTONOMIC_GANGLIA                          CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   RPMI; 10% FBS
  NB4_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE         CCLE                        AML                      haematopoietic_neoplasm                                      female   23     primary              RPMI; 10% FBS
  NCIH1299_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     43     metastasis           RPMI; 10% FBS
  NCIH1437_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     6      metastasis           RPMI; 10% FBS
  NCIH1581_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     44     primary              DMEM:F12 (1:1); 10% FBS
  NCIH1650_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     27     metastasis           RPMI; 10% FBS
  NCIH1693_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    female   55     metastasis           RPMI; 10% FBS
  NCIH1703_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     54     primary              RPMI; 10% FBS
  NCIH1792_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     50     metastasis           RPMI; 10% FBS
  NCIH1944_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    female   62     metastasis           RPMI; 10% FBS
  NCIH2023_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     26     metastasis           "DMEM:HAM's F12 (1:1); 5% FBS; .005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol, 10 mM HEPES, 2 mM L-glutamine"
  NCIH2030_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     metastasis           RPMI; 10% FBS
  NCIH2087_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     69     metastasis           RPMI; 5% FBS
  NCIH2110_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    NA       NA     metastasis           RPMI; 10% FBS
  NCIH2122_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    female   46     metastasis           RPMI; 10% FBS
  NCIH2126_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     65     metastasis           "DMEM:HAM's F12 (1:1); 5% FBS; .005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol, 10 mM HEPES, 2 mM L-glutamine"
  NCIH2170_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     primary              RPMI; 10% FBS
  NCIH2172_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    female   NA     primary              RPMI; 10% FBS
  NCIH2291_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     metastasis           RPMI; 10% FBS
  NCIH23_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    male     51     primary              RPMI; 10% FBS
  NCIH322_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     52     primary              RPMI; 10% FBS; 2mM glutamine
  NCIH441_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     metastasis           RPMI; 10% FBS
  NCIH460_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     metastasis           RPMI; 10% FBS
  NCIH520_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     primary              RPMI; 10% FBS
  NCIH716_LARGE_INTESTINE                        CCLE                        Colorectal               carcinoma                                                    male     33     metastasis           RPMI; 10% FBS
  NCIH747_LARGE_INTESTINE                        CCLE                        Colorectal               carcinoma                                                    male     69     metastasis           RPMI; 10% FBS
  NCIH838_LUNG                                   CCLE                        Lung (NSCLC)             carcinoma                                                    male     59     metastasis           RPMI; 10% FBS
  NCIN87_STOMACH                                 CCLE                        Stomach                  carcinoma                                                    male     NA     metastasis           RPMI; 10% FBS
  NOMO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE       CCLE                        AML                      haematopoietic_neoplasm                                      female   31     primary              RPMI; 10% FBS
  NUGC3_STOMACH                                  CCLE                        Stomach                  carcinoma                                                    male     72     primary              RPMI; 10% FBS
  OAW28_OVARY                                    CCLE                        Ovary                    carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS
  OE21_OESOPHAGUS                                CCLE                        Esophagus                carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  OE33_OESOPHAGUS                                CCLE                        Esophagus                other                                                        female   73     primary              RPMI; 10% FBS
  ONS76_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Medulloblastoma          primitive_neuroectodermal_tumour-medulloblastoma             NA       NA     NA                   RPMI; 10% FBS
  OSRC2_KIDNEY                                   CCLE                        Kidney                   carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  OUMS23_LARGE_INTESTINE                         CCLE                        Colorectal               carcinoma                                                    NA       NA     NA                   DMEM; 10% FBS
  OV7_OVARY                                      CCLE                        Ovary                    carcinoma                                                    female   78     primary              DMEM:F12 (1:1); 5% FBS; 2mM L-glutamine; 0.5ug/ml hydrocortisone; 10ug/ml insulin
  OV90_OVARY                                     CCLE                        Ovary                    carcinoma                                                    female   64     metastasis           DMEM; 10% FBS(Tony) \[1:1 mixture of MCDB 105 medium with 1.5 g/L sodium bicarbonate added and Medium 199; 10% FBS\]
  OVCAR8_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   64     primary              RPMI; 10% FBS
  OVISE_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   40     primary              RPMI; 10% FBS
  OVK18_OVARY                                    CCLE                        Ovary                    carcinoma                                                    NA       NA     NA                   MEM10
  OVMANA_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   51     primary              RPMI; 10% FBS
  OVTOKO_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   78     metastasis           RPMI; 10% FBS
  P31FUJ_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE      "Ebert Lab, DFCI"           AML                      haematopoietic_neoplasm                                      male     NA     NA                   RPMI; 10% FBS
  PANC0203_PANCREAS                              CCLE                        Pancreas                 carcinoma                                                    female   NA     NA                   RPMI; 10% FBS; 1mM sodium pyruvate
  PANC0403_PANCREAS                              CCLE                        Pancreas                 carcinoma                                                    male     NA     NA                   RPMI; 15% FBS; 20ug/ml human insulin
  PANC1005_PANCREAS                              CCLE                        Pancreas                 carcinoma                                                    male     NA     primary              RPMI; 15% FBS; 2mM glutamine; 1.5 g/L Sodium bicarbonate; 4.5g/L glucose; 10mM HEPES; 1mM Sodium Pyruvate; 10 units/mL Insulin
  PATU8988S_PANCREAS                             CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   "DMEM:;10%FBS, 2mMGlutamax"
  PC14_LUNG                                      CCLE                        Lung (NSCLC)             carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  PECAPJ34CLONEC12_UPPER_AERODIGESTIVE_TRACT     CCLE                        Upper Aerodigestive      carcinoma                                                    male     60     primary              IMDM; 10% FBS; 2mM Glutamine
  PF382_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE       "Steigmaier Lab, DFCI"      T-cell ALL               lymphoid_neoplasm                                            NA       NA     NA                   RPMI; 10% FBS
  PK1_PANCREAS                                   CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI-1640:10%FBS
  PK45H_PANCREAS                                 CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  PK59_PANCREAS                                  CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  PLCPRF5_LIVER                                  CCLE                        Liver                    carcinoma                                                    male     24     primary              DMEM; 10% FBS
  PSN1_PANCREAS                                  CCLE                        Pancreas                 carcinoma                                                    NA       NA     primary              RPMI; 10% FBS; 2mM glutamine
  RCC10RGB_KIDNEY                                CCLE                        Kidney                   carcinoma                                                    male     NA     primary              DMEM; 10% FBS
  RD_SOFT_TISSUE                                 CCLE                        Soft Tissue              rhabdomyosarcoma                                             female   7      primary              "DMEM:HAM's F12 (1:1); 5% FBS; .005 mg/ml insulin, .01 mg/ml transferrin, 30nM sodium selenite, 10 nM hydrocortisone, 10 nM beta estradiol, 10 mM HEPES, 2 mM L-glutamine"
  RERFLCAD1_LUNG                                 CCLE                        Lung (NSCLC)             carcinoma                                                    male     70     primary              RPMI; 10% FBS
  RERFLCAI_LUNG                                  CCLE                        Lung (NSCLC)             carcinoma                                                    male     NA     primary              EMEM; 10% FBS
  RH30_SOFT_TISSUE                               CCLE                        Soft Tissue              rhabdomyosarcoma                                             male     17     metastasis           RPMI; 10% FBS
  RKN_SOFT_TISSUE                                CCLE                        Ovary                    leiomyosarcoma                                               female   45     primary              Hams F-12; 10% FBS
  RKO_LARGE_INTESTINE                            CCLE                        Colorectal               carcinoma                                                    NA       NA     primary              MEM; 10% FBS
  RMUGS_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   62     primary              Hams F-12; 10% FBS
  RPMI7951_SKIN                                  CCLE                        Melanoma                 malignant_melanoma                                           female   18     metastasis           RPMI; 10% FBS
  RT112_URINARY_TRACT                            CCLE                        Urinary Tract            carcinoma                                                    female   NA     primary              RPMI; 10% FBS
  RT11284_URINARY_TRACT                          CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   EMEM; 10% FBS;2mMGlutamax; 1%NEAA
  RT4_URINARY_TRACT                              CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   M10
  RVH421_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           male     NA     NA                   RPMI; 10% FBS
  SCABER_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   "E10+ L-glutamine: 2.0 mM, NEAA( Non-essential Amino Acids): 0.1 mM, Sodium Pyruvate: 0.1 mM"
  SF295_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       female   67     primary              RPMI; 10% FBS
  SF767_CENTRAL_NERVOUS_SYSTEM                   "Lynda Chin, MD Anderson"   Glioma                   glioma                                                       female   NA     NA                   DMEM; 10% FBS
  SH10TC_STOMACH                                 CCLE                        Stomach                  carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  SIMA_AUTONOMIC_GANGLIA                         CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   RPMI; 10% FBS
  SJSA1_BONE                                     CCLE                        Osteosarcoma             osteosarcoma                                                 male     19     primary              RPMI; 10% FBS
  SKBR3_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   43     metastasis           McCoy's 5A; 10% FBS
  SKHEP1_LIVER                                   CCLE                        Liver                    carcinoma                                                    male     52     metastasis           EMEM; 10% FBS
  SKMEL24_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           male     67     metastasis           EMEM; 10% FBS
  SKMEL30_SKIN                                   CCLE                        Melanoma                 malignant_melanoma                                           male     67     metastasis           RPMI; 10% FBS
  SKMES1_LUNG                                    CCLE                        Lung (NSCLC)             carcinoma                                                    male     65     metastasis           DMEM; 10% FBS
  SKNAS_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                female   NA     NA                   DMEM; 10% FBS; NEAA
  SKNBE2_AUTONOMIC_GANGLIA                       CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   EMEM:F12 (1:1); 10% FBS
  SKNDZ_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                female   NA     NA                   DMEM; 10% FBS; NEAA
  SKNFI_AUTONOMIC_GANGLIA                        CCLE                        Neuroblastoma            neuroblastoma                                                male     NA     NA                   DMEM; 10% FBS; NEAA
  SKNMC_BONE                                     CCLE                        Ewing Sarcoma            Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour   female   NA     NA                   EMEM; 10% FBS
  SKOV3_OVARY                                    CCLE                        Ovary                    carcinoma                                                    female   64     metastasis           McCoy's 5A; 10% FBS
  SLR20_KIDNEY                                   "Kaelin Lab, DFCI"          Kidney                   carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  SLR23_KIDNEY                                   "Kaelin Lab, DFCI"          Kidney                   carcinoma                                                    NA       NA     primary              RPMI;10% FBS w/kanamycin
  SLR26_KIDNEY                                   "Kaelin Lab, DFCI"          Kidney                   carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  SNGM_ENDOMETRIUM                               CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   Ham F-12: 80.0%
  SNU1_STOMACH                                   CCLE                        Stomach                  carcinoma                                                    NA       NA     NA                   RPMI-1640: 90.0%
  SNU201_CENTRAL_NERVOUS_SYSTEM                  CCLE                        Glioma                   glioma                                                       male     58     primary              RPMI; 10% FBS
  SNU213_PANCREAS                                CCLE                        Pancreas                 carcinoma                                                    male     NA     NA                   "RPMI; 10% FBS, 2mM L-glutamine"
  SNU349_KIDNEY                                  CCLE                        Kidney                   carcinoma                                                    male     68     primary              RPMI; 10% FBS
  SNU398_LIVER                                   CCLE                        Liver                    carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  SNU410_PANCREAS                                CCLE                        Pancreas                 carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  SNU449_LIVER                                   CCLE                        Liver                    carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  SNU503_LARGE_INTESTINE                         CCLE                        Colorectal               carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  SNU685_ENDOMETRIUM                             CCLE                        Endometrium              carcinoma                                                    female   NA     NA                   RPMI; 10% FBS
  SNU8_OVARY                                     CCLE                        Ovary                    carcinoma                                                    female   55     primary              RPMI; 10% FBS
  SNU840_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   45     primary              RPMI; 10% FBS
  SUIT2_PANCREAS                                 CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  SUPM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE       "Weinstock Lab, DFCI"       T-cell Lymphoma (ALCL)   lymphoid_neoplasm                                            female   NA     NA                   RPMI; 20% FBS
  SUPT1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE       "Steigmaier Lab, DFCI"      T-cell ALL               lymphoid_neoplasm                                            male     8      metastasis           RPMI; 10% FBS
  SW1463_LARGE_INTESTINE                         CCLE                        Colorectal               carcinoma                                                    female   NA     NA                   RPMI; 10% FBS
  SW403_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    female   51     primary              Leibovitz's L-15; 10%FBS
  SW48_LARGE_INTESTINE                           CCLE                        Colorectal               carcinoma                                                    female   82     primary              RPMI; 10% FBS
  SW620_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    male     51     metastasis           L-15; 10% FBS
  SW837_LARGE_INTESTINE                          CCLE                        Colorectal               carcinoma                                                    male     53     primary              RPMI; 10% FBS
  T24_URINARY_TRACT                              CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   McCoy 5A: 90.0%
  T3M4_PANCREAS                                  CCLE                        Pancreas                 carcinoma                                                    NA       NA     NA                   Ham F-10: 90.0%;10%FBS
  T84_LARGE_INTESTINE                            CCLE                        Colorectal               carcinoma                                                    male     NA     NA                   DMEM:F12(1:1); 5% FBS; 2mM Glutamine
  T98G_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       male     61     primary              EMEM; 10% FBS
  TCCPAN2_PANCREAS                               CCLE                        Pancreas                 carcinoma                                                    female   NA     NA                   RPMI; 10% FBS
  TCCSUP_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    female   67     primary              EMEM; 10% FBS; 1mM NEAA; 1mM Sodium Pyruvate
  TE1_OESOPHAGUS                                 CCLE                        Esophagus                carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  TE5_OESOPHAGUS                                 CCLE                        Esophagus                carcinoma                                                    NA       NA     NA                   RPMI; 10% FBS
  TEN_ENDOMETRIUM                                CCLE                        Endometrium              carcinoma                                                    NA       NA     NA                   MEM;10%FBS
  TF1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE         CCLE                        AML                      haematopoietic_neoplasm                                      male     NA     NA                   RPMI-1640: 10%FBS; 2ng/ml GM-CSF
  THP1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE        CCLE                        AML                      haematopoietic_neoplasm                                      male     1      primary              RPMI; 10% FBS; 50uM B-mercaptoethanol
  TOV21G_OVARY                                   CCLE                        Ovary                    carcinoma                                                    female   62     primary              MCDB 105:Medium 199 (1:1); 15% FBS
  TUHR10TKB_KIDNEY                               CCLE                        Kidney                   carcinoma                                                    NA       NA     primary              RPMI; 10% FBS
  TUHR4TKB_KIDNEY                                CCLE                        Kidney                   carcinoma                                                    NA       NA     primary              DMEM; 10% FBS
  U118MG_CENTRAL_NERVOUS_SYSTEM                  CCLE                        Glioma                   glioma                                                       male     NA     primary              DMEM; 10% FBS
  U178_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       male     NA     NA                   DMEM; 10% FBS
  U251MG_CENTRAL_NERVOUS_SYSTEM                  CCLE                        Glioma                   glioma                                                       male     NA     primary              DMEM; 10% FBS
  U2OS_BONE                                      CCLE                        Osteosarcoma             osteosarcoma                                                 female   15     primary              McCoy's 5A; 10% FBS
  U343_CENTRAL_NERVOUS_SYSTEM                    "Lynda Chin, MD Anderson"   Glioma                   glioma                                                       NA       NA     NA                   DMEM; 10% FBS
  U87MG_CENTRAL_NERVOUS_SYSTEM                   CCLE                        Glioma                   glioma                                                       female   44     primary              EMEM; 10% FBS
  U937_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE        "Ebert Lab, DFCI"           Lymphoma (DLBCL)         lymphoid_neoplasm                                            male     37     metastasis           RPMI; 10% FBS
  UACC257_SKIN                                   CCLE                        Melanoma                 malignt_melanoma                                             NA       NA     primary              RPMI; 10% FBS
  UACC62_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     NA                   RPMI; 10% FBS
  UMUC3_URINARY_TRACT                            CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   EMEM; 10% FBS
  UOK101_KIDNEY                                  "Kaelin Lab, DFCI"          Kidney                   carcinoma                                                    female   NA     NA                   DMEM; 10% FBS
  VMCUB1_URINARY_TRACT                           CCLE                        Urinary Tract            carcinoma                                                    NA       NA     NA                   DMEM; 10%FBS
  WM115_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           female   NA     NA                   EMEM; 10% FBS
  WM1799_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     NA                   RPMI; 10% FBS
  WM2664_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           female   NA     NA                   DMEM; 10% FBS
  WM793_SKIN                                     CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     NA                   RPMI; 10% FBS
  WM983B_SKIN                                    CCLE                        Melanoma                 malignant_melanoma                                           NA       NA     NA                   RPMI; 10% FBS
  YAPC_PANCREAS                                  CCLE                        Pancreas                 carcinoma                                                    male     NA     NA                   RPMI; 10% FBS
  YKG1_CENTRAL_NERVOUS_SYSTEM                    CCLE                        Glioma                   glioma                                                       female   NA     primary              DMEM; 10% FBS
  ZR751_BREAST                                   CCLE                        Breast                   carcinoma                                                    female   NA     NA                   RPMI; 10% FBS
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